A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone or in combination with L19-IL2 as a treatment of metastatic FAP-positive solid tumors
Phase: Phase I clinical trials
Main Facility: Medicina Nucleare
Drug: [68Ga]Ga-OncoFAP (OncoFAP-DOTAGA marcato con 68Ga)
[177Lu]Lu-OncoFAP-23 (OncoFAP-23 marcato con 177Lu)
L19-IL2
Pathologies: Advanced Solid Tumours
The primary objective of this study is to assess the safety of [177Lu]Lu-OncoFAP-23 alone or in combination with L19-IL2 for the treatment of advanced/metastatic FAP-positive solid tumors and to establish a Recommended Dose (RD).
Last update: 20/04/2026